Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;65(11):3376-3390.
doi: 10.1111/epi.18119. Epub 2024 Sep 20.

In vivo biomarkers of GABAergic function in epileptic rats treated with the GAT-1 inhibitor E2730

Idrish Ali  1   2   3 , Bianca Jupp  1 , Matthew R Hudson  1 , Brendan Major  1 , Juliana Silva  1 , Glenn R Yamakawa  1 , Pablo M Casillas-Espinosa  1   2   3 , Emma Braine  1 , Peravina Thergarajan  1 , Mohammad B Haskali  4   5 , Lucy Vivash  1   2   3 , Robert Brkljaca  6 , Sandy R Shultz  1   3   7 , Patrick Kwan  1   2   3 , Kazuyuki Fukushima  8 , Pallavi Sachdev  9 , Jocelyn Y Cheng  9 , Richelle Mychasiuk  1 , Nigel C Jones  1   2   3 , David K Wright  1 , Terence J OBrien  1   2   3
Affiliations

In vivo biomarkers of GABAergic function in epileptic rats treated with the GAT-1 inhibitor E2730

Idrish Ali et al. Epilepsia. 2024 Nov.

Abstract

Objective: E2730, an uncompetitive γ-aminobutyric acid (GABA) transporter-1 (GAT-1) inhibitor, has potent anti-seizure effects in a rodent model of chronic temporal lobe epilepsy, the kainic acid status epilepticus (KASE) rat model. In this study, we examined purported neuroimaging and physiological surrogate biomarkers of the effect of E2730 on brain GABAergic function.

Methods: We conducted a randomized cross-over study, incorporating 1-week treatments with E2730 (100 mg/kg/day subcutaneous infusion) or vehicle in epileptic post-KASE rats. KASE rats underwent serial 9.4 T magnetic resonance spectroscopy (MRS) measuring GABA and other brain metabolites, [18F]Flumazenil positron emission tomography (PET) quantifying GABAA receptor availability, quantitative electroencephalography (qEEG) and transcranial magnetic stimulation (TMS)-mediated motor activity, as well as continuous video-EEG recording to measure spontaneous seizures during each treatment. Age-matched, healthy control animals treated with E2730 or vehicle were also studied.

Results: E2730 treatment significantly reduced spontaneous seizures, with 8 of 11 animals becoming seizure-free. MRS revealed that E2730-treated animals had significantly reduced taurine levels. [18F]Flumazenil PET imaging revealed no changes in GABA receptor affinity or density during E2730 treatment. The power of gamma frequency oscillations in the EEG was decreased significantly in the auditory cortex and hippocampus of KASE and control rats during E2730 treatment. Auditory evoked gamma frequency power was enhanced by E2730 treatment in the auditory cortex of KASE and healthy controls, but only in the hippocampus of KASE rats. E2730 did not influence motor evoked potentials triggered by TMS.

Significance: This study identified clinically relevant changes in multimodality imaging and functional purported biomarkers of GABAergic activity during E2730 treatment in epileptic and healthy control animals. These biomarkers could be utilized in clinical trials of E2730 and potentially other GABAergic drugs to provide surrogate endpoints, thereby reducing the cost of such trials.

Keywords: EEG; GABA; MRS; PET; biomarkers; mesial temporal lobe epilepsy.

PubMed Disclaimer

References

REFERENCES

    1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;3(342):314–319.
    1. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30‐year longitudinal cohort study. JAMA Neurol. 2018;1(75):279–286.
    1. Galanopoulou AS, Buckmaster PS, Staley KJ, Moshé SL, Perucca E, Engel J Jr, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia. 2012;53:571–582.
    1. Simonato M, French JA, Galanopoulou AS, O'Brien TJ. Issues for new antiepilepsy drug development. Curr Opin Neurol. 2013;26:195–200.
    1. Cook MJ, O'Brien TJ, Berkovic SF, Murphy M, Morokoff A, Fabinyi G, et al. Prediction of seizure likelihood with a long‐term, implanted seizure advisory system in patients with drug‐resistant epilepsy: a first‐in‐man study. Lancet Neurol. 2013;12:563–571.

MeSH terms

Grants and funding

LinkOut - more resources